The Patent Finder

Envivo Pharmaceuticals, Inc.

Also on record
Records under this name other than patents Envivo Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Envivo Pharmaceuticals, Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,273,044Crystalline Form of (R)-7-Chloro-N-(QUINUCLIDIN-3-YL)BENZO[B]THIOPHENE-2-Carboxamide Hydrochloride Monohydrate
Formerly held
Lapsed on the fee record
Ended Mar 1, 2024 · High confidence
Lapsed on the fee recordEnded Mar 1, 2024High confidence
US 9,108,961Crystalline Form of (R)-7-Chloro-N-(Quinuclidin-3-YL)benzo[B]thiophene-2-Carboxamide Hydrochloride Monohydrate
Lapsed on the fee record
Ended Aug 18, 2023 · High confidence
Lapsed on the fee recordEnded Aug 18, 2023High confidence
US 8,815,933Treatment of Cognitive Disorders with (R)-7-Chloro-N-(QUINUCLIDIN-3-YL)BENZO[B]THIOPHENE-2-Carboxamide and Pharmaceutically Acceptable Salts Thereof
Formerly held
Lapsed on the fee record
Ended Aug 26, 2022 · Medium confidence
Lapsed on the fee recordEnded Aug 26, 2022Medium confidence
US 8,710,227Crystalline Form of (R)-7-Chloro-N-(QUINUCLIDIN-3-YL)BENZO[B]THIOPHENE-2-Carboxamide Hydrochloride Monohydrate
Formerly held
Lapsed on the fee record
Ended Apr 29, 2022 · High confidence
Lapsed on the fee recordEnded Apr 29, 2022High confidence
US 8,642,638Treatment of Cognitive Disorders with (R)-7-Chloro-N-(QUINUCLIDIN-3-YL)BENZO[B]THIOPHENE-2-Carboxamide and Pharmaceuticall Acceptable Salts Thereof
Formerly held
Lapsed on the fee record
Ended Feb 4, 2022 · Medium confidence
Lapsed on the fee recordEnded Feb 4, 2022Medium confidence
US 8,569,354Treatment of Cognitive Disorders with (R)-7-Chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-Carboxamide and Pharmaceutically Acceptable Salts Thereof
Formerly held
Lapsed on the fee record
Ended Oct 29, 2021 · Medium confidence
Lapsed on the fee recordEnded Oct 29, 2021Medium confidence
US 8,466,1481,2-Disubstituted Heterocyclic Compounds
Formerly held
Lapsed on the fee record
Ended Jun 18, 2021 · High confidence
Lapsed on the fee recordEnded Jun 18, 2021High confidence
US 8,399,452DIBENZO[B,F][1,4]OXAZEPIN-11-YL-N-HYDROXYBENZAMIDES as Hdac Inhibitors
Formerly held
Lapsed on the fee record
Ended Mar 19, 2021 · High confidence
Lapsed on the fee recordEnded Mar 19, 2021High confidence
US 9,550,767Crystalline Form of (R)-7-Chloro-N-(Quinuclidin-3-YL)benzo[B]thiophene-2-Carboxamide Hydrochloride Monohydrate
Formerly held
Lapsed on the fee record
Ended Jan 24, 2021 · High confidence
Lapsed on the fee recordEnded Jan 24, 2021High confidence
US 9,540,380Imidazotriazinone Compounds
Formerly held
Lapsed on the fee record
Ended Jan 10, 2021 · Medium confidence
Lapsed on the fee recordEnded Jan 10, 2021Medium confidence
10 of 23 patents shown.
Pro members see all 23.
Pro members: see all 23 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited